The lawsuits claim Teva struck deals to settle patent suits with Gilead that delayed the introduction of a generic form of Viread until December 2017 and generic forms of Truvada and Atripla until ...

News, January 29, 2008 International Approvals: Humira, Atripla, Januvia Europe has approved a new indication for adalimumab subcutaneous injection (Humira) and efavirenz/emtricitabine/tenofovir ...

The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, ...

As a former trial attorney with more than a decade of litigation experience, Jamie L. Pfeiffer writes trustworthy, engaging and informative content for law firm websites, legal publications and ...

The first cross-class fixed-dose combination, Atripla, was developed by Gilead and Bristol–Myers Squibb (BMS), and launched in 2006 in the United States. This once-daily pill containing an NNRTI ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of ...

(Nasdaq: GILD) announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of ...

Emily Field, an analyst from Barclays, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

Tenofovir is available as tablets (300mg) and in fixed-dose combinations with emtricitabine (Truvada ®) and with emtricitabine plus efavirenz (Atripla ®); the latter combination was recently ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...